Petr Pohlreich

Summary

Affiliation: Charles University
Country: Czech Republic

Publications

  1. ncbi request reprint [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]
    P Pohlreich
    Ústav biochemie a experimentální onkologie, 1 LF UK a VFN v Praze
    Klin Onkol 25:S59-66. 2012
  2. pmc High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area
    Petr Pohlreich
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Breast Cancer Res 7:R728-36. 2005
  3. doi request reprint Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene
    Ivana Ticha
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Breast Cancer Res Treat 124:337-47. 2010
  4. doi request reprint The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development
    Zdenek Kleibl
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    J Cancer Res Clin Oncol 137:331-8. 2011
  5. doi request reprint Expression of human BRCA1Δ17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response
    Jan Sevcik
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, CZ 128 53 Prague 2, Czech Republic
    Cell Signal 25:1186-93. 2013
  6. ncbi request reprint Contribution of mutations in ATM to breast cancer development in the Czech population
    Jana Soukupova
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Oncol Rep 19:1505-10. 2008
  7. ncbi request reprint Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations
    Zdenek Kleibl
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Breast Cancer Res Treat 112:159-64. 2008
  8. ncbi request reprint High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University, Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    J Genet 86:169-71. 2007
  9. ncbi request reprint Novel complex genomic rearrangement of the BRCA1 gene
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, First Medical School of Charles University, U nemocnice 5, 128 00, Prague, Czech Republic
    Mutat Res 637:205-8. 2008
  10. pmc Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
    Petra Kleiblova
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ 12853 Prague, Czech Republic
    J Cell Biol 201:511-21. 2013

Collaborators

Detail Information

Publications17

  1. ncbi request reprint [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]
    P Pohlreich
    Ústav biochemie a experimentální onkologie, 1 LF UK a VFN v Praze
    Klin Onkol 25:S59-66. 2012
    ..The risk of cancer development associated with alterations in these genes is lower, and there is a considerable population variability in different regions worldwide...
  2. pmc High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area
    Petr Pohlreich
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Breast Cancer Res 7:R728-36. 2005
    ..The purpose of our study was to estimate the incidence and spectrum of pathogenic mutations in BRCA1/2 genes in high-risk Czech families...
  3. doi request reprint Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene
    Ivana Ticha
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Breast Cancer Res Treat 124:337-47. 2010
    ..Implementation of chromosome-specific aCGH could markedly facilitate the design of primers for amplification and sequence analysis of junction fragments, especially in deletions overlapping gene boundaries...
  4. doi request reprint The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development
    Zdenek Kleibl
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    J Cancer Res Clin Oncol 137:331-8. 2011
    ..Recently, polyglutamine (poly-Q) repeat length polymorphism of the amplified in breast cancer 1 (AIB1) gene was analyzed as a risk factor influencing BC onset in BRCA1/2 mutation carriers with contradictory results...
  5. doi request reprint Expression of human BRCA1Δ17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response
    Jan Sevcik
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, CZ 128 53 Prague 2, Czech Republic
    Cell Signal 25:1186-93. 2013
    ..Our findings indicate that expression of BRCA1Δ17-19 may negatively influence genome stability by reducing the DDSB repair velocity, thereby contributing to enhanced probability of cancer development in the affected families...
  6. ncbi request reprint Contribution of mutations in ATM to breast cancer development in the Czech population
    Jana Soukupova
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Oncol Rep 19:1505-10. 2008
    ..Our experiments did not detect the hypermethylation of the ATM promoter in any of the DNA samples from tumor tissues...
  7. ncbi request reprint Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations
    Zdenek Kleibl
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Breast Cancer Res Treat 112:159-64. 2008
    ..Despite the lack of association of I157T mutation with breast cancer development in our population we deduced that the FHA domain is the subject of rare population-specific alterations that might modify risk of various cancers...
  8. ncbi request reprint High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University, Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    J Genet 86:169-71. 2007
  9. ncbi request reprint Novel complex genomic rearrangement of the BRCA1 gene
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, First Medical School of Charles University, U nemocnice 5, 128 00, Prague, Czech Republic
    Mutat Res 637:205-8. 2008
    ..This rearrangement involves exons 21 and 22 and results in a protein product lacking BRCT domain important for its function...
  10. pmc Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
    Petra Kleiblova
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ 12853 Prague, Czech Republic
    J Cell Biol 201:511-21. 2013
    ..We show that mutations in PPM1D affect the DDR pathway and propose that they could predispose to cancer...
  11. doi request reprint The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer
    Marketa Janatova
    Authors Affiliations Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague Institutes of Biology and Medical Genetics and Pathology, and Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
    Cancer Epidemiol Biomarkers Prev 22:2323-32. 2013
    ..We analyzed the prevalence and spectrum of germline mutations in PALB2 to estimate their contribution to hereditary breast and/or ovarian cancer in the Czech Republic...
  12. ncbi request reprint Novel somatic mutations in the BRCA1 gene in sporadic breast tumors
    Marketa Janatova
    Department of Biochemistry and Experimental Oncology, Charles University in Prague, Prague, Czech Republic
    Hum Mutat 25:319. 2005
    ..The occurrence of inactivating somatic mutations in sporadic breast tumors suggested the role of the BRCA1 gene in tumorigenesis in at least a minor group of patients with non-familial breast cancer...
  13. doi request reprint The BRCA1 alternative splicing variant Δ14-15 with an in-frame deletion of part of the regulatory serine-containing domain (SCD) impairs the DNA repair capacity in MCF-7 cells
    Jan Sevcik
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    Cell Signal 24:1023-30. 2012
    ....
  14. doi request reprint Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients
    Jana Soukupova
    Department of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University, U nemocnice 5, 128 53, Prague, Czech Republic
    Neuromolecular Med 13:204-11. 2011
    ....
  15. ncbi request reprint The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic
    Zdenek Kleibl
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U nemocnice 5, Prague, 12853, Czech Republic
    Breast Cancer Res Treat 90:165-7. 2005
    ..1100delC mutation varies among different populations. Based on our results, genotyping of CHEK2 c.1100delC mutation in clinical settings in the Czech Republic could not be recommended...
  16. ncbi request reprint The role of ATM in breast cancer development
    Jana Prokopcova
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Breast Cancer Res Treat 104:121-8. 2007
    ..Second, in vitro studies of heterozygous cells provide strong evidence of hyperradiosensitivity. Third, some clinical studies found an increased frequency of ATM mutations among high-risk breast cancer families...
  17. doi request reprint The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population
    Zdenek Kleibl
    Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Eur J Cancer 45:618-24. 2009
    ..We observed no association of analysed mutations with CRC family history. We conclude that the I157T and other alterations in its proximity predispose to sporadic but not to familial CRC in the Czech population...